| Literature DB >> 22297133 |
Stanislav Sokolenko1, Steve George, Andreas Wagner, Anup Tuladhar, Jonas M S Andrich, Marc G Aucoin.
Abstract
The baculovirus expression vector system (BEVS) is a versatile and powerful platform for protein expression in insect cells. With the ability to approach similar post-translational modifications as in mammalian cells, the BEVS offers a number of advantages including high levels of expression as well as an inherent safety during manufacture and of the final product. Many BEVS products include proteins and protein complexes that require expression from more than one gene. This review examines the expression strategies that have been used to this end and focuses on the distinguishing features between those that make use of single polycistronic baculovirus (co-expression) and those that use multiple monocistronic baculoviruses (co-infection). Three major areas in which researchers have been able to take advantage of co-expression/co-infection are addressed, including compound structure-function studies, insect cell functionality augmentation, and VLP production. The core of the review discusses the parameters of interest for co-infection and co-expression with time of infection (TOI) and multiplicity of infection (MOI) highlighted for the former and the choice of promoter for the latter. In addition, an overview of modeling approaches is presented, with a suggested trajectory for future exploration. The review concludes with an examination of the gaps that still remain in co-expression/co-infection knowledge and practice. Copyright ÂEntities:
Mesh:
Substances:
Year: 2012 PMID: 22297133 PMCID: PMC7132753 DOI: 10.1016/j.biotechadv.2012.01.009
Source DB: PubMed Journal: Biotechnol Adv ISSN: 0734-9750 Impact factor: 14.227
Use of chaperones to improve protein production.
| Chaperone | Protein | Host | Expression | Effect | Reference | ||
|---|---|---|---|---|---|---|---|
| Name | Promoter | Name | Promoter | ||||
| BiP | α4GnT | Silkworm larvae | Co-injection (with Bacmid) | Increased activity | |||
| α4GnT | Silkworm larvae | Co-injection (with Bacmid) | Increased activity | ||||
| Myc-SERT | Sf9 | Co-infection | Small increase in activity | ||||
| IgG | Tn-5B1-4 | Co-infection | Increased solubility processed light chain | ||||
| IgG | Tn-5B1-4 | Co-infection | Increased solubility and secretion | ||||
| IgG | Sf9 | Co-infection | Increased solubility but not secretion | ||||
| Calnexin | α4GnT | Silkworm larvae | Co-injection (with Bacmid) | Increased activity | |||
| α4GnT | Silkworm larvae | Co-injection (with Bacmid) | Increased activity | ||||
| GFPUV-βGnT2 | Tn-5B1-4 | Co-infection | Increased secretion, increased extracellular activity | ||||
| Lipoprotein lipase | Sf21 | Co-infection | Increased activity | ||||
| Shaker potassium channel | Sf9 | Co-infection | Increased activity (correctly folded) | ||||
| Myc-SERT | Sf9 | Co-infection | Increased activity | ||||
| Taurine transporter | Sf9 | Co-infection | Increased activity | ||||
| Calreticulin | GFPUV-βGnT2 | Tn-5B1-4 | Co-infection | Increased secretion | |||
| Lipoprotein lipase | Sf21 | Co-infection | Large increase in activity | ||||
| Myc-SERT | Sf9 | Co-infection | Small increase in activity | ||||
| DnaK, DnaJ | mGFP | Co-expression | Increased solubility | ||||
| mGFP | Sf9 | Co-expression | Increased expression (less degradation) | ||||
| N/A | FMDV VP1 | N/A | Sf9 | Co-infection | Increased solubility | ||
| N/A | FMDV VP2 | N/A | Sf9 | Co-infection | Less aggregate formation | ||
| N/A | human alpha-galactosidase | N/A | Sf9 | Co-infection | Increased solubility | ||
| ERp57 | α4GnT | Silkworm larvae | Co-injection (with Bacmid) | Increased activity | |||
| Hsp70 | BZLF1 | Tn-5B1-4 | Co-infection | Small increase in solubility | |||
| IgG | Tn-5B1-4 | Co-infection | Increased solubility light chain precursor | ||||
| Hsp70, Hsdj | [ | BZLF1 | Tn-5B1-4 | Co-infection | Increase in solubility | ||
| Hsp70, Hsp40 | [ | BZLF1 | Tn-5B1-4 | Co-infection | Increase in solubility | ||
| PDI | Lipoprotein lipase | Sf21 | Co-infection | Slight increase in activity | |||
| IgG | Tn-5B1-4 | Co-infection | Recover insoluble immunoglobulins | ||||
[] refers to those proteins produced from a single virus.
polh: polyhedrin promoter.
p10: p10 promoter.
Ie-2: Ie-2 promoter from Orgyia pseudotsugata MNPV.
Virus-like particles produced by co-infection/co-expression of multiple viral structural proteins.
| Virus name | Production strategy | Proteins expressed (promoter) | Reference |
|---|---|---|---|
| Enveloped VLPs | |||
| Parvovirus B19 | Co-expression using a bicistronic baculovirus | [VP1 ( | |
| Co-infection using two monocistronic baculoviruses | VP1 ( | ||
| Blue tongue virus | Co-expression using a bicistronic baculovirus | [VP3 ( | |
| Combined co-infection and co-expression with two baculoviruses | [VP2 ( | ||
| Co-expression using quadruple-cistronic baculoviruses | [VP2 ( | ||
| Chimeric BTV—epizootic hemorrhagic disease virus particles | Co-infection using two monocistronic baculoviruses | EHDV VP3 ( | |
| Co-infection using two monocistronic baculoviruses and one bicistronic baculovirus | EHDV VP3 ( | ||
| Rotavirus | Co-infection using two monicistronic baculoviruses | VP2 ( | |
| Co-infection using three monocistronic baculoviruses | VP2 ( | ||
| Co-infection using three monocistronic baculoviruses | VP2 ( | ||
| Co-infection using four monocistronic baculoviruses | VP2 ( | ||
| Poliovirus | Co-expression from a single baculovirus with poliovirus coding region | VP0, VP1, VP3 ( | |
| Co-infection using three monocistronic baculovirus | VP0 ( | ||
| Co-infection using one monocistronic baculovirus and one bicistronic baculovirus | [VP0 ( | ||
| Enterovirus 71 | Co-infection using two monocistronic baculoviruses | P1 ( | |
| Co-expression using a bicistronic baculovirus | [P1 ( | ||
| Human papillomavirus (HPV) | Co-expression using one bicistronic baculovirus | [L1 ( | |
| Co-infection using two monocistronic baculoviruses | L1 ( | ||
| Herpes simplex virus (HSV) | Co-infection using up to six monocistronic baculoviruses | VP23 ( | |
| Marek's disease virus (MDV) | Co-infection using up to six monocistronic baculoviruses | MDV homologues of HSV proteins VP23 ( | |
| Simian virus 40 (SV40) | Co-infection using three monocistronic viruses | VP1 ( | |
| Adeno associated virus (AAV) | Co-infection using two monocistronic viruses | VP2 ( | |
| Enveloped VLPs | |||
| Influenza | Co-expression using a quadruple recombinant baculovirus | [HA ( | |
| Co-expression using a tricistronic baculovirus | [HA ( | ||
| Co-infection using one monocistronic and one bicistronic baculovirus | [HA ( | ||
| Co-infection using two monocistronic baculoviruses | HA ( | ||
| Co-infection using three monocistronic baculoviruses | H5N1 HA ( | ||
| Simian immunodeficiency virus (SIV) | Co-infection using two monocistronic baculoviruses | Gag ( | |
| Human immunodeficiency virus (HIV) | Co-infection using two monocistronic baculoviruses | Gag ( | |
| Co-infection using two monocistronic baculoviruses | Gag ( | ||
| Co-expression using a bicistronic baculovirus | [Gag ( | ||
| Co-infection using two monocistronic baculoviruses | Gag ( | ||
| Feline leukaemia virus (FeLV) | Co-infection using two monocistronic baculoviruses | Gag ( | |
| Hepatitis B virus (HBV) | Co-expression using a bicistronic baculovirus | [Core antigen ( | |
| SARS coronavirus | Co-infection using three monocistronic baculoviruses | Spike ( | |
| Co-expression using a tricistronic baculovirus | [Spike ( | ||
| Ebolavirus | Co-infection using two monocistronic baculoviruses | VP40 ( | |
| Hantaan virus | Co-infection using two monocistronic baculoviruses | Nucleocapsid protein ( | |
[] refers to those proteins produced from a single virus.
polh: polyhedrin promoter.
p10: p10 promoter.
Pcap/polh: hybrid capsid/polyhedrin promoter.